ReviewClinical and experimental immunology2008
Allergy and the eye.
Review in Clinical and experimental immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis.The Cochrane database of systematic reviews · 2015Pooled it
- Hydrocortisone concentration influences time to clinically significant healing of acute inflammation of the ocular surface and adnexa - results from a double-blind randomized controlled trial.BMC ophthalmology · 2014Trial
- Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating procedures.Investigative ophthalmology & visual science · 2013Trial
- Olopatadine Exerts Multifaceted Protective Effects in an Ovalbumin-Induced Allergic Eye Disease Mouse Model.Bioengineering (Basel, Switzerland) · 2026Article
- Clinical and epidemiological profiles of vernal keratoconjunctivitis in a tertiary care setting: Association of disease pattern with recurrent attacks.Indian journal of ophthalmology · 2026Observational
- Bispecific nanobodies targeting Bet v 1 and ICAM-1 decrease respiratory epithelial penetration of Bet v 1.Frontiers in immunology · 2026Article
- Article
- Traditional Chinese medicine-related interventions for allergic conjunctivitis and vernal keratoconjunctivitis: clinical evidence, mechanistic hypotheses, and ocular surface safety considerations.Frontiers in medicine · 2026Review
- Hypersensitivity in Orthodontics: A Systematic Review of Oral and Extra-Oral Reactions.Journal of clinical medicine · 2025Review
- Lebanese Medicinal Plants with Ophthalmic Properties.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- The evolving role of ciclosporin in the management of vernal keratoconjunctivitis.Frontiers in ophthalmology · 2025Review
- The Prevalence of Accommodative and Binocular Dysfunctions in Children with Reading Difficulties.Life (Basel, Switzerland) · 2024Article
- Review
- Trans-eyelid distribution of epinastine to the conjunctiva following eyelid application in rabbits.Japanese journal of ophthalmology · 2024Article
- Allergic Conjunctivitis: Review of Current Types, Treatments, and Trends.Life (Basel, Switzerland) · 2024Review
- A Patient-Centered Approach to Vernal Keratoconjunctivitis (VKC): A Podcast.Ophthalmology and therapy · 2024Article
- Looking beyond Self-Protection: The Eyes Instruct Systemic Immune Tolerance Early in Life.Brain sciences · 2023Article
- Preserved Ophthalmic Anti-Allergy Medication in Cumulatively Increasing Risk Factors of Corneal Ectasia.Biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The eye represents an ideal and frequent site for the allergic reactions. The term 'allergic conjunctivitis' refers to a collection of disorders that affect the lid, conjunctiva and/or cornea. Even though the diagnosis is essentially clinical, local tests such as cytology, conjunctival provocation and tear mediator analysis can be performed. The immunoglobulin E (IgE)-mediated mechanism does not explain completely the severity and the clinical course of chronic allergic ocular diseases such as vernal (VKC) and atopic keratoconjunctivitis (AKC), which are probably also related to T cell-mediated responses, massive eosinophil attraction and activation and non-specific hypersensitivity. An altered balance between T helper type 1 (Th1) and Th2 cells and between Th1- and Th2-types of cytokines is thought to be responsible of the development of ocular allergic disorders. New findings suggest that a wide range of cytokines, chemokines, proteases and growth factors are involved by complex interwoven interactions rather than distinct and parallel pathways. In addition, several non-specific enzymatic systems may be activated during acute and chronic allergic inflammation, thus contributing to the complex pathogenesis of the disease. Current drug treatment for ocular allergy targets the key mechanisms involved in the development of clinical disease: mast cells with mast cell stabilizers, histamine with histamine receptor antagonists and inflammation with corticosteroids, severe inflammation with immunomodulators. None of these agents lacks side effects and none abolishes signs and symptoms completely. New therapeutic strategies are still needed to respond to the complex pathogenesis of severe forms of ocular allergy such as VKC and AKC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.